TargetedTherapies ?

Recent international survey showed high global EGFR testing rates prior to first-line lung cancer therapy but highlighted a shortfall in the number of test results received before deciding on therapy.

Nearly one in five patients are at risk of missing out on treatments personalised to their specific lung cancer type.

 

Read the article: http://www.biospace.com/News/boehringer-ingelheim-hcp-survey-nearly-20-of-newly/441293